Upstream Bio, Inc./$UPB
Upstream Bio jumps after announcing positive top-line Phase 2 VIBRANT trial results for verekitug in CRSwNP showing significant reduction in nasal polyp scores.
6 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Upstream Bio, Inc.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
Ticker
$UPB
Sector
Primary listing
Employees
52
Headquarters
Website
UPB Metrics
BasicAdvanced
$923M
-
-$2.82
-
-
Price and volume
Market cap
$923M
52-week high
$19.37
52-week low
$5.14
Average daily volume
479K
Financial strength
Current ratio
38.272
Quick ratio
36.254
Long term debt to equity
0.208
Total debt to equity
0.382
Profitability
EBITDA (TTM)
-121.423
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3,836.58%
Operating margin (TTM)
-4,464.60%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-22.85%
Return on equity (TTM)
-32.49%
Valuation
Price to revenue (TTM)
245.525
Price to book
2.25
Price to tangible book (TTM)
2.25
Price to free cash flow (TTM)
-5.837
Free cash flow yield (TTM)
-17.13%
Free cash flow per share (TTM)
-2.935
Growth
Revenue change (TTM)
22.60%
Earnings per share change (TTM)
-84.28%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Upstream Bio, Inc. stock?
Upstream Bio, Inc. (UPB) has a market cap of $923M as of September 03, 2025.
What is the P/E ratio for Upstream Bio, Inc. stock?
The price to earnings (P/E) ratio for Upstream Bio, Inc. (UPB) stock is 0 as of September 03, 2025.
Does Upstream Bio, Inc. stock pay dividends?
No, Upstream Bio, Inc. (UPB) stock does not pay dividends to its shareholders as of September 03, 2025.
When is the next Upstream Bio, Inc. dividend payment date?
Upstream Bio, Inc. (UPB) stock does not pay dividends to its shareholders.
What is the beta indicator for Upstream Bio, Inc.?
Upstream Bio, Inc. (UPB) does not currently have a Beta indicator.